The AHA appreciates the Medicare Payment Advisory Commission’s concerns about rising pharmaceutical costs and urged the Commission to continue to take action to achieve sustainable drug pricing. “Hospitals, and the clinicians who work in them, know firsthand the lifesaving potential of drug therapies … however, an unaffordable drug is not a lifesaving drug,” AHA said in a letter to MedPAC commissioners. AHA shared recommendations with MedPAC, including mandating an average sales price inflation cap for Medicare Part B and Part D drugs, and applying the cap to both high-cost and lower-cost drugs; identifying approaches to preventing excessively high launch prices as a response to an ASP inflation cap; maintaining the ASP plus 6 percent payment methodology for Part B drugs; testing a new Part D payment model that reduces or eliminates reinsurance payments while making appropriate adjustments to the direct subsidy rate; and improving annual public reports on Medicare Part B and Part D drug costs by making them more consumer and provider-friendly.

Related News Articles

Headline
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
Headline
The American Society for Health Care Engineering is supporting the ongoing efforts of hospital and health systems to fight COVID-19 in their communities by…
Headline
Thirty-three emerging hospital and health system leaders from 20 states will participate in the inaugural class of the AHA’s Next Generation Leaders Fellowship…
Headline
Community Health Improvement Week (June 1-5) celebrates people coming together to create healthier communities. And that's never been more important than now…
Headline
The Centers for Medicare & Medicaid Services yesterday released a fact sheet for state and local governments seeking Medicare, Medicaid or Children’s…
Headline
Over 1,750 Medicare Part D prescription drug plans and Medicare Advantage plans with prescription drug coverage have applied to offer lower insulin costs…